在BRAF突变的转移性非小细胞肺癌中，达拉非尼联合曲美替尼出现毒性后成功转换为维莫非尼联合考比替尼治疗 - Suppr

Suppr

超能文献

Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAF-Mutant Metastatic Non-Small-Cell Lung Cancer.

作者信息

Chic Nuria, Mezquita Laura, Aldea Mihaela, Chebib Ralph, Caramella Caroline, Planchard David, Besse Benjamin

机构信息

Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.

Medical Oncology Department, Gustave Roussy, Villejuif, France.

出版信息

Clin Lung Cancer. 2021 Jan;22(1):e54-e56. doi: 10.1016/j.cllc.2020.07.013. Epub 2020 Aug 5.

DOI:10.1016/j.cllc.2020.07.013

PMID:32896487

Abstract

摘要

相似文献

Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAF-Mutant Metastatic Non-Small-Cell Lung Cancer.在BRAF突变的转移性非小细胞肺癌中，达拉非尼联合曲美替尼出现毒性后成功转换为维莫非尼联合考比替尼治疗

Clin Lung Cancer. 2021 Jan;22(1):e54-e56. doi: 10.1016/j.cllc.2020.07.013. Epub 2020 Aug 5.

Adverse Event Management in Patients with V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib.V600E 突变型非小细胞肺癌患者接受达拉非尼联合曲美替尼治疗的不良事件管理。

Oncologist. 2019 Jul;24(7):963-972. doi: 10.1634/theoncologist.2018-0296. Epub 2018 Dec 31.

Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy.获得性BRAF V600E突变介导对奥希替尼耐药并对奥希替尼、达拉非尼和曲美替尼联合治疗有反应。

J Thorac Oncol. 2019 Oct;14(10):e236-e237. doi: 10.1016/j.jtho.2019.05.040.

Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition.原发性中枢神经系统转移性BRAF突变型肺腺癌对BRAF/MEK抑制呈现完全颅内反应

Clin Lung Cancer. 2020 Nov;21(6):e544-e546. doi: 10.1016/j.cllc.2020.05.006. Epub 2020 May 12.

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.达拉非尼联合曲美替尼治疗既往接受过治疗的BRAF（V600E）突变转移性非小细胞肺癌患者：一项开放标签、多中心2期试验。

Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6.

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.达拉非尼联合曲美替尼与维莫非尼联合考比替尼用于既往未治疗的转移性黑色素瘤患者的间接治疗比较

J Hematol Oncol. 2017 Jan 4;10(1):3. doi: 10.1186/s13045-016-0369-8.

An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.在对达拉非尼加曲美替尼耐药的BRAF V600E突变型肺腺癌中获得性NRAS Q61K突变

J Thorac Oncol. 2018 Aug;13(8):e131-e133. doi: 10.1016/j.jtho.2018.03.026. Epub 2018 Apr 6.

Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma.接受达拉非尼和曲美替尼治疗的 BRAF V600E 阳性肺腺癌患者的肉芽肿性多血管炎。

BMC Cancer. 2020 Mar 4;20(1):177. doi: 10.1186/s12885-020-6661-6.

Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma.评估达拉非尼联合曲美替尼方案治疗 BRAF 突变型晚期黑色素瘤患者的疗效与 dabrafenib-trametinib 预后分组的相关性。

Melanoma Res. 2020 Jun;30(3):268-271. doi: 10.1097/CMR.0000000000000634.

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.达拉非尼和曲美替尼联合治疗剂量降低用于治疗 BRAF V600E 突变型非小细胞肺癌可预防横纹肌溶解并维持肿瘤缩小：病例报告。

BMC Cancer. 2020 Feb 24;20(1):156. doi: 10.1186/s12885-020-6626-9.

引用本文的文献

Non-small-cell lung cancer: how to manage -mutated disease.非小细胞肺癌：如何治疗携带 - 突变的疾病。（注：原文中“-mutated”处信息不完整，推测是有具体基因名称等，但按现有内容翻译如此）

Drugs Context. 2023 May 2;12. doi: 10.7573/dic.2022-11-3. eCollection 2023.

Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study.BRAF和MEK抑制剂在同类转换后用于转移性黑色素瘤的耐受性：一项多中心回顾性研究

Cancers (Basel). 2023 Feb 23;15(5):1426. doi: 10.3390/cancers15051426.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验